ST. LOUIS, Jan. 14, 2020 /PRNewswire/ -- Centene
Corporation (NYSE:CNC) ("Centene") announced today the extension of
the expiration date of the offers to exchange (the "Exchange
Offers") notes (the "WellCare Notes") issued by WellCare Health
Plans, Inc. (NYSE:WCG) ("WellCare") for up to $1,950,000,000 aggregate principal amount of new
notes to be issued by Centene (the "Centene Notes") and cash and
the related consent solicitations (the "Consent Solicitations")
being made by Centene on behalf of WellCare to adopt certain
proposed amendments (the "Amendments") to the indentures governing
the WellCare Notes. Centene hereby extends such expiration date
from 5:00 p.m., New York City time, on January 14, 2020, to 5:00
p.m., New York City time,
on January 21, 2020 (as the same may
be further extended, the "Expiration Date").
On November 14, 2019, requisite
consents were received and supplemental indentures were executed,
eliminating substantially all restrictive covenants and certain
events of default and other provisions in each of the indentures
governing the WellCare Notes. Such supplemental indentures will
only become operative upon the settlement date of the Exchange
Offers.
The Exchange Offers and Consent Solicitations are being made
pursuant to the terms and subject to the conditions set forth in
the confidential offering memorandum and consent solicitation
statement dated November 1, 2019, as
amended on November 12, 2019 and the
related letter of transmittal and consent hereby, each as amended
by the press releases dated December 2,
2019, December 18, 2019 and
January 8, 2020 and as amended
hereby, and are conditioned upon the closing of Centene's
acquisition of WellCare (the "Merger"), which condition may not be
waived by Centene, and certain other conditions that may be waived
by Centene.
The settlement date for the Exchange Offers is expected to occur
promptly after the Expiration Date and immediately prior to the
closing of the Merger, which is expected to occur by the first half
of 2020. As a result, the Expiration Date may be further extended
one or more times. Centene will provide notice of any such
extension in advance of the Expiration Date.
Except as described in this press release, all other terms of
the Exchange Offers and Consent Solicitations remain unchanged.
As of 5:00 p.m., New York City time, on January 14, 2020, the principal amounts of
WellCare Notes set forth in the table below had been validly
tendered and not validly withdrawn:
|
WellCare Notes
Tendered as of 5:00 p.m.,
New York City time, on January 14, 2020
|
Title of
Series/CUSIP
Number
|
Principal
Amount
Outstanding
|
Principal
Amount
|
Percentage
|
5.25% Senior Notes
due
2025 / 94946TAC0
|
$1,200,000,000
|
$1,145,775,000
|
95.48%
|
5.375% Senior Notes
due
2026 / 94946TAD8 /
U9488LAB8
|
$750,000,000
|
$747,168,000
|
99.62%
|
Documents relating to the Exchange Offers and Consent
Solicitations will only be distributed to eligible holders of
WellCare Notes who complete and return an eligibility form
confirming that they are either a "qualified institutional buyer"
under Rule 144A or not a "U.S. person" and outside the United States under Regulation S for
purposes of applicable securities laws. Except as amended by the
press releases dated December 2,
2019, December 18, 2019 and
January 8, 2020 and as amended
hereby, the complete terms and conditions of the Exchange Offers
and Consent Solicitations are described in the confidential
offering memorandum and consent solicitation statement dated
November 1, 2019 as amended on
November 12, 2019 and the related
letter of transmittal and consent, copies of which may be obtained
by contacting Global Bondholder Services Corporation, the exchange
agent and information agent in connection with the Exchange Offers
and Consent Solicitations, at (866) 470-4200 (U.S. toll-free) or
(212) 430-3774 (banks and brokers). The eligibility form is
available electronically
at: https://gbsc-usa.com/eligibility/centene.
This press release does not constitute an offer to sell or
purchase, or a solicitation of an offer to sell or purchase, or the
solicitation of tenders or consents with respect to, any security.
No offer, solicitation, purchase or sale will be made in any
jurisdiction in which such an offer, solicitation or sale would be
unlawful. The Exchange Offers and Consent Solicitations are being
made solely pursuant to the offering memorandum and consent
solicitation statement dated November 1,
2019, as amended on November 12,
2019 and as amended by the press releases dated December 2, 2019, December
18, 2019 and January 8, 2020
and as amended hereby and the related letter of transmittal and
consent, and only to such persons and in such jurisdictions as are
permitted under applicable law.
The Centene Notes offered in the Exchange Offers have not been
registered under the Securities Act of 1933, as amended, or any
state securities laws. Therefore, the Centene Notes may not be
offered or sold in the United
States absent registration or an applicable exemption from
the registration requirements of the Securities Act of 1933, as
amended, and any applicable state securities laws.
About Centene Corporation
Centene Corporation, a Fortune 100 company, is a diversified,
multi-national healthcare enterprise that provides a portfolio of
services to government sponsored and commercial healthcare
programs, focusing on under-insured and uninsured individuals. Many
receive benefits provided under Medicaid, including the State
Children's Health Insurance Program (CHIP), as well as Aged, Blind
or Disabled (ABD), Foster Care and Long-Term Services and
Supports (LTSS), in addition to other state-sponsored
programs, Medicare (including
the Medicare prescription drug benefit commonly known as
"Part D"), dual eligible programs and programs with the U.S.
Department of Defense. Centene also provides healthcare
services to groups and individuals delivered through commercial
health plans. Centene operates local health plans and
offers a range of health insurance solutions. It also contracts
with other healthcare and commercial organizations to provide
specialty services including behavioral health management, care
management software, correctional healthcare services, dental
benefits management, commercial programs, home-based primary care
services, life and health management, vision benefits management,
pharmacy benefits management, specialty pharmacy and telehealth
services.
Cautionary Statement Regarding Forward-Looking
Statements
All statements, other than statements of current or historical
fact, contained in this communication are forward-looking
statements. Without limiting the foregoing, forward-looking
statements often use words such as "believe," "anticipate," "plan,"
"expect," "estimate," "intend," "seek," "target," "goal," "may,"
"will," "would," "could," "should," "can," "continue" and other
similar words or expressions (and the negative thereof). In
particular, these statements include, without limitation,
statements about Centene's intended use of proceeds from the
offering, future operating or financial performance, market
opportunity, growth strategy, competition, expected activities in
completed and future acquisitions, including statements about the
impact of the Merger, Centene's recent acquisition (the "Fidelis
Care Transaction") of substantially all the assets of New York State Catholic Health Plan, Inc.,
d/b/a Fidelis Care New York ("Fidelis
Care"), investments and the adequacy of Centene's available
cash resources.
These forward-looking statements reflect Centene's current views
with respect to future events and are based on numerous assumptions
and assessments made by Centene in light of Centene's experience
and perception of historical trends, current conditions, business
strategies, operating environments, future developments and other
factors Centene believes appropriate. By their nature,
forward-looking statements involve known and unknown risks and
uncertainties and are subject to change because they relate to
events and depend on circumstances that will occur in the future,
including economic, regulatory, competitive and other factors that
may cause Centene's or its industry's actual results, levels of
activity, performance or achievements to be materially different
from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking
statements. These statements are not guarantees of future
performance and are subject to risks, uncertainties and
assumptions.
All forward-looking statements included in this communication
are based on information available to Centene on the date of this
communication. Except as may be otherwise required by law, Centene
undertakes no obligation and expressly disclaims any obligation to
update or revise the forward-looking statements included in this
communication, whether as a result of new information, future
events or otherwise, after the date of this communication. You
should not place undue reliance on any forward-looking statements,
as actual results may differ materially from projections,
estimates, or other forward-looking statements due to a variety of
important factors, variables and events including, but not limited
to, the following: (i) the risk that regulatory or other approvals
required for the Merger may be delayed or not obtained or are
obtained subject to conditions that are not anticipated that could
require the exertion of management's time and Centene's resources
or otherwise have an adverse effect on Centene; (ii) the
possibility that certain conditions to the consummation of the
Merger will not be satisfied or completed on a timely basis and
accordingly the Merger may not be consummated on a timely basis or
at all; (iii) uncertainty as to the expected financial performance
of the combined company following completion of the Merger; (iv)
the possibility that the expected synergies and value creation from
the Merger will not be realized, or will not be realized within the
expected time period; (v) the exertion of management's time and
Centene's resources, and other expenses incurred and business
changes required, in connection with complying with the
undertakings in connection with any regulatory, governmental or
third party consents or approvals for the Merger; (vi) the risk
that unexpected costs will be incurred in connection with the
completion and/or integration of the Merger or that the integration
of WellCare will be more difficult or time consuming than expected;
(vii) the risk that potential litigation in connection with the
Merger may affect the timing or occurrence of the Merger, cause it
not to close at all, or result in significant costs of defense,
indemnification and liability; (viii) a downgrade of the credit
rating of Centene's indebtedness, which could give rise to an
obligation to redeem existing indebtedness; (ix) unexpected costs,
charges or expenses resulting from the Merger; (x) the inability to
retain key personnel; (xi) disruption from the announcement,
pendency and/or completion of the Merger, including potential
adverse reactions or changes to business relationships with
customers, employees, suppliers or regulators, making it more
difficult to maintain business and operational relationships; (xii)
the risk that, following the Merger, the combined company may not
be able to effectively manage its expanded operations, (xiii)
Centene's ability to accurately predict and effectively manage
health benefits and other operating expenses and reserves; (xiv)
competition; (xv) membership and revenue declines or unexpected
trends; (xvi) changes in healthcare practices, new technologies and
advances in medicine; (xvii) increased healthcare costs, (xviii)
changes in economic, political or market conditions; (xix) changes
in federal or state laws or regulations, including changes with
respect to income tax reform or government healthcare programs as
well as changes with respect to the Patient Protection and
Affordable Care Act and the Health Care and Education Affordability
Reconciliation Act, collectively referred to as the Affordable Care
Act ("ACA"), and any regulations enacted thereunder that may result
from changing political conditions or judicial actions, including
the ultimate outcome of the District Court decision in "Texas v.
United States of America"
regarding the constitutionality of the ACA; (xx) rate cuts or other
payment reductions or delays by governmental payors and other risks
and uncertainties affecting Centene's government businesses; (xxi)
Centene's ability to adequately price products on federally
facilitated and state-based Health Insurance Marketplaces; (xxii)
tax matters; (xxiii) disasters or major epidemics; (xxiv) the
outcome of legal and regulatory proceedings; (xxv) changes in
expected contract start dates; (xxvi) provider, state, federal and
other contract changes and timing of regulatory approval of
contracts; (xxvii) the expiration, suspension, or termination of
Centene's contracts with federal or state governments (including,
but not limited to, Medicaid, Medicare, TRICARE or other
customers); (xxviii) the difficulty of predicting the timing or
outcome of pending or future litigation or government
investigations; (xxix) challenges to Centene's contract awards;
(xxx) cyber-attacks or other privacy or data security incidents;
(xxxi) the possibility that the expected synergies and value
creation from acquired businesses, including, without limitation,
the Fidelis Care Transaction, will not be realized, or will not be
realized within the expected time period; (xxxii) the exertion of
Centene management's time and Centene's resources, and other
expenses incurred and business changes required in connection with
complying with the undertakings in connection with any regulatory,
governmental or third party consents or approvals for acquisitions;
(xxxiii) disruption caused by significant completed and pending
acquisitions, including, among others, the Fidelis Care
Transaction, making it more difficult to maintain business and
operational relationships; (xxxiv) the risk that unexpected costs
will be incurred in connection with the completion and/or
integration of acquisition transactions; (xxxv) changes in expected
closing dates, estimated purchase price and accretion for
acquisitions; (xxxvi) the risk that acquired businesses, including
Fidelis Care, will not be integrated
successfully; (xxxvii) the risk that Centene may not be able to
effectively manage its operations as they have expanded as a result
of the Fidelis Care Transaction; (xxxviii) restrictions and
limitations in connection with Centene's indebtedness; (xxxix)
Centene's ability to maintain or achieve improvement in the Centers
for Medicare and Medicaid Services star ratings and maintain or
achieve improvement in other quality scores in each case that can
impact revenue and future growth; (xl) availability of debt and
equity financing on terms that are favorable to Centene; (xli)
inflation; and (xlii) foreign currency fluctuations.
This list of important factors is not intended to be exhaustive.
Centene discusses certain of these matters more fully, as well as
certain other factors that may affect Centene's business
operations, financial condition and results of operations, in
Centene's filings with the Securities and Exchange Commission (the
"SEC"), including the registration statement on Form S-4 filed by
Centene with the SEC on May 23, 2019,
and Centene's Annual Report on Form 10-K, quarterly reports on Form
10-Q and current reports on Form 8-K. Due to these important
factors and risks, Centene cannot give assurances with respect to
Centene's future performance, including without limitation
Centene's ability to maintain adequate premium levels or Centene's
ability to control its future medical and selling, general and
administrative costs.
View original
content:http://www.prnewswire.com/news-releases/centene-corporation-announces-extension-of-exchange-offers-and-consent-solicitations-for-wellcare-notes-300987099.html
SOURCE Centene Corporation